Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD

Kristina Maas-Bauer, MD, of the University of Freiburg, discusses preclinical research on the role of ROCK1/2 in graft-vs-host disease (GVHD), which found an effect on myeloid cells, both in phenotype profile and migration capabilities. Additionally, she discusses the potential of combining ROCK1/2 inhibitors with ruxolitinib for refractory GVHD.